請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61342
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蕭斐元 | |
dc.contributor.author | Hung-Lin Chen | en |
dc.contributor.author | 陳虹霖 | zh_TW |
dc.date.accessioned | 2021-06-16T13:01:19Z | - |
dc.date.available | 2017-09-24 | |
dc.date.copyright | 2013-09-24 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-08-07 | |
dc.identifier.citation | 參考文獻
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians. Jan 2013;63(1):11-30. 2. 健康統計資訊:Y98-癌症登記年度報告(全). . 行政院衛生署國民健康局. 2012:(Accessed at http://www.bhp.doh.gov.tw/BHPNet/Web/Stat/StatisticsShow.aspx?No=200911300001). 3. 醫藥產業年鑑, Yearbook of pharmaceutical industry 生物技術開發中心. 2004-2012. 4. 趙月秀. 癌症治療藥物市場潛力及發展趨勢 , Current status and trends in the development of cancer therapeutics. 生物技術開發中心. 2006. 5. Joshua Cohen* LFaKG. Mapping Biopharmaceutical Innovation and Diffusion: How the Second Translational Block (T2) Shapes Drug Diffusion. The Open Pharmacology Journal. 2008;2:89-106. 6. Network NCC. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. National Comprehensive Cancer Network. 2013;2:(Accessed at http://www.nccn.org/index.asp). 7. Frank C. Detterbeck, Sandra Zelman Lewis, Rebecca Diekemper, Doreen J. Addrizzo-Harris, Alberts aWM. Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest. 2013;143(5 (suppl)):7s-37s. 8. 王麗桂. 台灣非小細胞肺癌介入標靶藥物治療使用. 高雄醫學大學醫務管理學研究所碩士論文. 2010. 9. Joseph T. Dipiro, Robert L. Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. Wells, and L. Michael Posey ea. Pharmacotherapy: A Pathophysiologic Approach, 8th Ed. New York: McGraw-Hill Medical. 2011. 10. Vince D. Cataldo, Don L. Gibbons, Roman Perez-Soler, Quintas-Cardama aA. Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib. NEJM. 2011;364:947-955. 11. Makoto Maemondo MD, Ph.D., Akira Inoue, M.D., Ph.D., Kunihiko Kobayashi, M.D., Ph.D., Shunichi Sugawara, M.D., Ph.D., et al. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR. NEJM. 2010;362:2380-2388. 12. Angela Mariotto EJF, Linda C. Harlan, Lap-Ming Wun, Karen A., Johnson JA. Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975–1999. Journal of the National Cancer Institute. 2002;94:1626-1634. 13. Schoffski O. Impediments to the Diffusion of Innovative Medicines in Europe. Pharmacoeconomics 2004;22 Suppl(2):51-64. 14. Rogers EM. Diffusion of innovations, 5th ed. New York : Free Press. 2003. 15. Ahmedin Jemal, Freddie Bray, Melissa M. Center, Jacques Ferlay, Elizabeth Ward, Forman aD. Global Cancer Statistics. CA: a cancer journal for clinicians. 2011;61:69-90. 16. K. Hotta KM, H. Ueoka, K. Kiura, M. Tabata, and M. Tanimoto. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Annals of Oncology. 2004; 15:1782-1789. 17. Roy S. Herbst MD, Ph.D., John V. Heymach, M.D., Ph.D., and Scott M. Lippman, M.D. Molecular Origins of Cancer, Lung Cancer. NEJM. 2008;359:1367-1380. 18. Fortunato Ciardiello MD, Ph.D., and Giampaolo Tortora, M.D., Ph.D. EGFR Antagonists in Cancer Treatment. NEJM. 2008;358:1160-1174. 19. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clinical cancer research : an official journal of the American Association for Cancer Research. Feb 1 2006;12(3 Pt 1):839-844. 20. Yang CH, Shih JY, Chen KC, et al. Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer. Cancer. Oct 15 2006;107(8):1873-1882. 21. 徐心馨. 晚期非小細胞肺癌患者腫瘤組織之表皮生長因子受體基因突變與化學治療結果之關聯性研究. 國立台灣大學臨床藥學碩士論文. 2006. 22. Jiang H. Overview of Gefitinib in Non-small Cell Lung Cancer: An Asian Perspective. Jpn J Clin Oncol 2009;39(3):137–150. 23. Mark G. Kris M, Ronald B. Natale, MD, Roy S. Herbst, MD, et al. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial. JAMA. 2003;290(16):2149-2158. 24. Tony S. Mok MD, Yi-Long Wu, M.D., F.A.C.S., Sumitra Thongprasert, M.D., Chih-Hsin Yang, M.D., Ph.D., et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. NEJM. 2009;361:947-957. 25. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Mar 10 2013;31(8):1039-1049. 26. MICROMEDEXR 2.0. Truven Health Analytics.(Accessed at http://www.micromedexsolutions.com/micromedex2/librarian). 27. 健保用藥品項查詢. 行政院衛生署 中央健康保險局. 2013:(Accessed at http://www.nhi.gov.tw/Query/query1.aspx?menu=18&menu_id=703). 28. Azzoli CG, Baker S, Jr., Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Dec 20 2009;27(36):6251-6266. 29. 石尊元. 新藥於台灣醫院間擴散性探討-以Thiazolidinediones實證研究為例. 國立陽明大學醫務管理碩士論文. 2007. 30. Trisha Greenhalgh ea. Diffusion of innovations in health service organisations : a systematic literature review. Malden, Mass. : Blackwell. 2005. 31. Prosser H, Walley T. New drug prescribing by hospital doctors: the nature and meaning of knowledge. Social science & medicine. Apr 2006;62(7):1565-1578. 32. 孫玉齡. 醫師採用創新產品之影響因素-以採用心臟支架之情境為例. 國立政治大學科技管理碩士論文. 2011. 33. 任冠安. 醫師新藥採用行為之決定因素-以藥品新穎性為干擾變項. 長庚大學工商管理碩士論文. 2011. 34. Garjon FJ, Azparren A, Vergara I, Azaola B, Loayssa JR. Adoption of new drugs by physicians: a survival analysis. BMC health services research. 2012;12:56. 35. Vijay Mahajan EMaFMB. New Product Diffusion Models in Marketing: A Review and Directions for Research. Journal of Marketing. 1990;54(1):1-26. 36. Liu YM, Yang YH, Hsieh CR. The determinants of the adoption of pharmaceutical innovation: evidence from Taiwan. Social science & medicine. Mar 2011;72(6):919-927. 37. Coleman JS, Katz E, and Menzel H. Medical Innovation:A Diffusion Study. New York:Bobbs-Merrill.PH(E). 1966. 38. Mason A. New medicines in primary care: a review of influences on general practitioner prescribing. Journal of Clinical Pharmacy and Therapeutics 2008;33:1-10. 39. Carpenter WR, Reeder-Hayes K, Bainbridge J, et al. The role of organizational affiliations and research networks in the diffusion of breast cancer treatment innovation. Medical care. Feb 2011;49(2):172-179. 40. Hsiao FY, Tsai YW, Huang WF. Price regulation, new entry, and information shock on pharmaceutical market in Taiwan: a nationwide data-based study from 2001 to 2004. BMC health services research. 2010;10:218. 41. Danil V. Makarov M, MHS, et al. The Association Between Diffusion of the Surgical Robot and Radical Prostatectomy Rates. Medical care. 2011;49:333–339. 42. William R. Carpenter M, PhD, et al. The Role of Provider-based Research Networks in the Diffusion of an Evidence-based Colon Cancer Treatment Innovation. Medical care. 2012;50:737-748. 43. 鄭智文. 全民健保制度下醫院處方集對結腸直腸癌用藥可近性之影響探討. 國立台灣大學衛生政策與管理碩士論文. 2009. 44. 佘宛臻. 新上市藥品之擴散探討-以三高藥品為例. 國立陽明大學醫務管理碩士論文. 2011. 45. Sebastiao Loureiroa FM, Lucio Freitasc, Claudio Leaod, Erika Aragaoe. Diffusion of new drugs: a review on the available empirical evidence focused on developing countries. European Community’s 6th Framework Programme. 2010. 46. Vakratsas D, Kolsarici C. A dual-market diffusion model for a new prescription pharmaceutical. International Journal of Research in Marketing. 2008;25(4):282-293. 47. 施維宜. 使用gefitinib或化學治療對末期非小細胞肺癌病患的醫療費用及成本效果分析. 國立台灣大學臨床藥學碩士論文. 2008. 48. 張凱瑛. 探討首次治療型態對非小細胞肺癌各期別病患存活情形之影響. 國立陽明大學衛生福利碩士論文. 2010. 49. 朱育增, 吳肖琪. 回顧與探討次級資料適用之共病測量方法. 台灣衛誌. 2010;29(1):8-21. 50. 張柏印. 第四期非小細胞肺癌病人終身醫療成本分析與醫療成本推估模式之建立. 國立台灣大學臨床藥學碩士論文. 51. 台灣癌症中心資料庫. 肺癌. 行政院衛生署國民健康局. 2006. 52. Rena M. Conti, and AB, Meltzer DO. How do initial signals of quality influence the diffusion of new medical products? The case of new cancer drug treatments. Advances in Health Economics and Health Services Research. 2012;23:123-148. 53. Jennifer L. Lund, Til Stu‥rmer, Hanna K. Sanoff, Alan Brookhart, Robert S. Sandler a, L.Warren J. Determinants of Adjuvant Oxaliplatin Receipt Among Older Stage II and III Colorectal Cancer Patients. Cancer. 2013;119:2038-2047. 54. Mary Ann Gilligan, Ronald T. Kneusel, Raymond G. Hoffmann, Ann L. Greer, Nattinger aAB. Persistent Differences in Sociodemographic Determinants of Breast Conserving Treatment Despite Overall Increased Adoption. Medical care. 2002;40(3):181-189. 55. C. Martin TAMMEMAGI, Christine NESLUND-DUDAS, Michael SIMOFF, KVALE aP. Impact of Comorbidity on Lung Cancer Survival. Int J Cancer. 2003;103: 792-802. 56. 徐千惠. 運用計劃行為理論探討醫師處方決策之影響因素-以非小細胞肺癌化學治療藥物為例. 國立中正大學企業管理碩士論文. 2006. 57. Hospital Characteristics and Use of Innovative Surgical Therapies Among Patients With Kidney Cancer. 58. 歐凰姿. 醫院競爭與處方行為之關係-以門診糖尿病口服降血糖藥品治療為例. 國立成功大學臨床藥學碩士論文. 2005. 59. Chiang TA, Chen PH, Wu PF, et al. Important prognostic factors for the long-term survival of lung cancer subjects in Taiwan. BMC cancer. 2008;8:324. 60. National Cancer Institute: Comprehensive Cancer Information. 2013:(Accessed at http://www.cancer.gov/). 61. Robyn Tamblyn, Peter Mcleod, James A. Hanley, Nadyne Girard, Hurley aJ. Physician and Practice Characteristics Associated with the Early Utilization of New Prescription Drugs. Medical care. 2003;41(8):895–908. 62. 章殷超, 溫在弘, 賴美淑. 利用地理資訊系統探討肝癌病患就醫地理可近性與醫院選擇間之相關性. 台灣衛誌. 2009;28(6):517-529. 63. Linda E Levesque, James A Hanley, Abbas Kezouh, Suissa aS. Research methods & Reporting: Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:907-911. 64. Zheng Zhou, Elham Rahme, Michal Abrahamowicz, Pilote aL. Survival Bias Associated with Time-to-Treatment Initiation in Drug Effectiveness Evaluation: A Comparison of Methods. Am J Epidemiol. 2005;162:1016-1023. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61342 | - |
dc.description.abstract | 研究背景:
創新新藥gefitinib和erlotinib這兩個標靶藥物對於末期非小細胞肺癌病人的臨床療效,在隨機性臨床試驗中已被證實。然而,過去研究指出新藥自上市後到被病人所廣泛地使用,仍因各種層面的阻礙,而可能延遲一段相當長的時間,使得病患無法及時接受到最新的治療。 研究目的: 本觀察性研究的目的在於探討在台灣健康保險制度下,非小細胞肺癌病人接受標靶藥物治療在各層面的影響因素,並進一步分析早中晚三期接受者之間的不同,以及其影響程度。 研究方法: 使用台灣健保資料庫承保抽樣檔和癌症登記檔作為資料來源,篩選出2004年到2009年間1,555位新診斷為非小細胞肺癌且接受藥物治療的病患。根據病患是否接受標靶藥物的治療,將病患分為新藥接受組與未接受組;其中的新藥接受組,進一步依照病患接受標靶藥物的時間點先後,依序分組為早期(小於140天)、中期(140-390天)和晚期接受者(大於390天),並分別利用邏輯式迴歸以及多分類邏輯式迴歸分析上述不同接受者之間的影響因素。 研究結果: 研究期間接受標靶藥物(新藥接受組)的病患共計562人(36.1%),而未接受組為993人(63.9%)。而新藥接受組的病患依照得到標靶藥物的時間點,可進一步區分為早期接受者(n=141,25%)、中期接受者(n=277,50%)和晚期接受者(n=144人,25%)。 邏輯式迴歸分析發現病患接受到標靶藥物的治療,顯著受到下列因素影響。年齡越大(OR=0.42; 95%CI: 0.29-0.61)及男性病患(OR=0.75; 95%CI: 0.59-0.96),接受到標靶藥物治療的機會較低;若病患罹患的是末期癌症(OR=1.44; 95%CI: 1.14-1.81 )和腺肺癌(OR=2.95; 95%CI: 2.10-4.16),則接受到標靶藥物治療的機會較高。若病患的就診醫院為私立醫院(OR=1.35; 95%CI: 1.03-1.78)且經濟規模愈大(OR=2.67; 95%: 1.79-3.98)時,則病患接受到標靶藥物治療的機會較高。 多分類邏輯式迴歸分析發現,比起中期(OR=0.40; 95%CI: 0.25-0.63)和晚期接受者(OR=0.21; 95%CI: 0.12-0.36),早期接受者受到放寬新藥給付規範的更動影響最大。除了健保給付規定的影響外,比起中期(OR=0.28; 95%CI: 0.11-0.68)和晚期接受者(OR=0.21; 95%CI: 0.08-0.55),腺肺癌的病患傾向於在早期得到標靶藥物的治療,此符合現下非小細胞肺癌的國際臨床治療準則。 研究結論: 本研究結果顯示非小細胞肺癌病患是否接受到標靶藥物的治療,與病患/腫瘤、醫師、醫院和政策各層面的影響因素有關。而病患接受到標靶藥物治療的時間點早晚,則會受到病患基本性質、疾病嚴重程度以及健保給付規範更動的影響。 | zh_TW |
dc.description.abstract | Background: Molecular targeted drugs (MTD), gefitinib and erlotinib, have been proven to provide clinical benefit to end-stage non-small cell lung cancer (NSCLC) patients in randomized clinical trials (RCTs). Although RCTs are generally regarded as the highest level of evidence, studies have shown substantial lag time before results are incorporated into clinical practice. Therefore, access to such medical innovation in time is critical for patients who need it.
Objectives: The aim of this population-based observational study is to explore multi-aspect determinants of adoption of MTD among NSCLC patients, analyze the likelihood of different users under Taiwan’s National Health Insurance (NHI) system. Methods: Using Taiwan's Longitudinal Health Insurance Database and Cancer Registry as data source, we identified 1,555 newly diagnosed NSCLC patients who initiated their cancer treatment between 2004 and 2009. Patients were categorized into 'non-MTD' and 'MTD' based on the cancer treatment they received. 'MTD' were further categorized as 'early ', 'mid-term' and 'late' users if they receive their MTD within 140 days, during 140-390 days, and after 390 days after the initial cancer treatment of NSCLC, respectively. Logistic regression and multi-nominal logistic regressions were conducted to explore potential determinants associated with the adoption pattern of MTD. Results: During the study period, 562 (36.1%) NSCLC patients adopt MTD, as 'MTD', and 993 (63.9%) patients were 'non-MTD'. Owing to strict reimbursement criteria, 348 (62%) 'MTD' were involved in the second-line and third-line MTD therapy. Among 562 cancer patients who received MTD, early user takes up 141 (25%), mid user takes up 277 (50%) and late user takes up 144 (25%). Logistic regression shows that patients receiving MTD is significantly associated with older age (OR=0.42; 95%CI: 0.29-0.61), male (OR=0.75; 95%CI: 0.59-0.96), end stage (OR=1.44; 95%CI: 1.14-1.81 ), adenocarcinoma (OR=2.95; 95%CI: 2.10-4.16), private hospital (OR=1.35; 95%CI: 1.03-1.78) and bigger economic scale (OR=2.67; 95%: 1.79-3.98). Compared with early users, multi-nominal logistic regression model shows mid-term users (OR=0.40; 95%CI: 0.25-0.63) and late users (OR=0.21; 95%CI: 0.12-0.36) are less influenced by policy intervention. In addition, patients with adenocarcinoma adopted MTD at early stage compared with mid users (OR=0.28; 95%CI: 0.11-0.68) and late users (OR=0.21; 95%CI: 0.08-0.55). The result is consistent with the current international clinical guideline of NSCLC. Conclusions: Our findings suggest that patient/tumor-, physician-, hospital- and policy-level impact factors significantly deterred the adoption of MTD among NSCLC patients. When it comes to the timing of adopting MTD, we found that it was influenced mostly by policy intervention and patient characteristics. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T13:01:19Z (GMT). No. of bitstreams: 1 ntu-102-R99451008-1.pdf: 1584282 bytes, checksum: 85bf9553b7f2c02f47217474812af7fd (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 中文摘要 i
Abstract iii 目錄 vi 表目錄 ix 圖目錄 x 第一章 前言 1 第二章 文獻探討 3 2.1 非小細胞肺癌簡介及其治療 3 2.1.1 簡介 3 2.1.2 流行病學 3 2.1.3 臨床分級與治療準則 3 2.1.3.1傳統化療 4 2.1.3.2標靶治療 4 2.1.3.3標靶藥物的優勢及適應症 5 2.1.4國外臨床治療指引與國內健保給付規定 5 2.1.4.1國外治療指引對於標靶藥物的使用建議 5 2.1.4.2台灣全民健康保險簡介 6 2.1.4.3國內健保對於gefitinib和erlotinib的藥品給付規定 6 2.2 創新擴散理論(Diffusion of innovation) 9 2.2.1簡介 9 2.2.2採用創新者分類及特性介紹 9 2.2.3組織創新的採用特性 10 2.3醫藥領域之新藥擴散影響因素 12 2.3.1創新特性 12 2.3.2病患疾病 13 2.3.3醫師屬性 13 2.3.4醫院組織 13 2.3.5政府政策 14 第三章 研究目的 17 第四章 研究方法 18 4.1資料來源 18 4.1.1 台灣全民健保資料庫承保抽樣百萬歸人檔 18 4.1.2台灣癌症登記檔 18 4.2研究族群、研究架構與研究分組之建立 19 4.2.1研究架構 19 4.2.2研究世代的納入與排除條件 21 4.2.3研究期間定義 24 4.2.4研究分組定義 25 4.2.5研究變項處理 25 4.2.6研究變項與操作型定義 27 4.3統計分析 30 4.3.1研究族群之描述性統計分析 30 4.3.2邏輯式迴歸分析 30 4.3.3多分類邏輯性迴歸分析 31 第五章 研究結果 33 5.1研究族群之建立 33 5.2描述性統計結果 33 5.2.1研究族群背景資料分析 34 5.2.2早中晚期接受者背景資料描述 39 5.3推論性統計結果 44 5.3.1接受標靶新藥相關因子之單變項邏輯式迴歸分析 44 5.3.2接受標靶新藥相關因子之多變項邏輯式迴歸分析 48 5.3.3接受標靶新藥時間點早晚之單變項分類式邏輯迴歸分析 50 5.3.4接受標靶新藥時間點早晚之多變項分類式邏輯迴歸分析 52 第六章 討論 56 6.1研究族群背景資料分析 56 6.1.1基本資料分析 56 6.1.2研究族群接受化學治療處方分析 57 6.1.3標靶新藥接受時間點早晚的處方分析 58 6.2非小細胞肺癌病患接受標靶新藥的影響因素分析 60 6.2.1病患特性 60 6.2.2疾病嚴重程度 60 6.2.3醫師服務量 61 6.2.4醫院特性 62 6.2.5政策層面 62 6.3首次接受標靶新藥時間早晚的影響因素分析 64 6.3.1病患特性與疾病 64 6.3.2醫師與醫院服務 65 6.3.3健保給付層面 65 6.4非小細胞肺癌接受標靶新藥時間點相關存活分析 66 6.5研究優勢與限制 67 第七章 結論與建議 69 參考文獻 70 | |
dc.language.iso | zh-TW | |
dc.title | 全民健康保險制度下採用標靶新藥於非小細胞肺癌病患之處方型態分析 | zh_TW |
dc.title | Adoption of New Molecular Targeted Drug among Non-Small Lung Cancer Patients under National Health Insurance System in Taiwan | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 沈麗娟 | |
dc.contributor.oralexamcommittee | 魏志平,楊志新,溫有汶 | |
dc.subject.keyword | 採用,全民健康保險研究資料庫,標靶藥物,非小細胞肺癌, | zh_TW |
dc.subject.keyword | Adoption,National Health Insurance Research Database(NHIRD),molecular targeted drug(MTD),non-small cell lung cancer(NSCLC), | en |
dc.relation.page | 74 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2013-08-07 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 1.55 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。